OTHER GROUP COMPANIES
market

Zydus Lifesciences acquire rights to market MonoFerric injections in India and Nepal

Zydus is a market leader in the Nephrology area, with products including Oxemia, Zyrop, Renocrit, Kbind, Grafalon, Tacromus, and Mycomune.

September 09, 2022 1:12 IST | India Infoline News Service
Zydus Lifesciences Ltd., a worldwide life sciences company focused on innovation, announced that it has acquired the rights to sell MonoFerric in India and Nepal from Pharmacosmos A/S based in Denmark.

MonoFerric, iron isomaltoside 1000 injection/infusion solution, is a fast, single dose IV iron (up to 20 mg/kg body weight) created to minimise the number of infusions needed to accomplish iron correction while maintaining a strong safety profile.

MonoFerric is used to treat iron deficiency in adults when oral iron preparations are inefficient or cannot be administered, or when there is a clinical requirement for iron to be delivered quickly. MonoFerric is accessible in over 30 countries, including the United States and Europe, and more than 28 million doses have been provided since its introduction.

Zydus is a market leader in the Nephrology area, with products including Oxemia, Zyrop, Renocrit, Kbind, Grafalon, Tacromus, and Mycomune.

At around 1.14 PM, Zydus Lifesciences was trading at Rs376.30 up by 0.53% from its previous closing of Rs374.30 on the BSE. The scrip touched intraday high and low of Rs381.40 and Rs372.50 respectively.

For feedback and suggestions, write to us at editorial@iifl.com

Invest wise with Expert advice

FEATURED ARTICLE

BLOGS

Open Demat Account

Invest wise with Expert advice

By continuing, I accept the Terms & Conditions and agree to receive updates on Whatsapp